420 Magazine Background

A Double-Blind, Controlled Trial Of Nabilone Vs. Prochlorperazine For Refractory

Truth Seeker

New Member
27 patients who were refractory to previously used common antiemetic treatment while on chemotherapy have been entered in a crossover, double-blind, randomized study aimed to compare efficacy and toxicity of 2 mg b.i.d. oral nabilone and 10 mg b.i.d. oral prochlorperazine. Eighteen patients are presently evaluable for efficacy. Severity of nausea was less during the nabilone period of administration. The number of vomiting ejections and dry retching episodes was significantly less (P<0.001) on nabilone than on prochlorperazine. There was a significant period effect (P<0.01) together with the patient's evaluation of vomiting episodes and the investigator's assessment of therapeutic efficacy, the vomiting scores being worse during the second treatment period. 72% of the patients (P<0.05) preferred nabilone to prochlorpearzine, in agreement with the observed therapeutic efficacy. Side effects (54%) were more frequent and severe with nabilone than with prochlorperazine; postural hypotension (42%), which was severe in 7 patients with a fall of more than 30 mm Hg. Vertigo (23%), CNS changes (headache, depression, general weakness-4%; mood alterations with dysphoria-8%). Nabilone showed activity against cis-platinum- (50 mg/m2) and adriamycin-plus-cyclophosphamide-induced vomiting

Source: Clinical Studies and Case Reports
Top Bottom